Form 4: Executive Andrew Boyer Reports Stock Transactions in Amneal Pharmaceuticals
SEC Form 4 Filing
Executive Vice President Andrew Boyer reports the vesting of restricted stock units and subsequent stock transactions in Amneal Pharmaceuticals.
Summary
- On March 1, 2025, Andrew Boyer, an Executive Vice President at Amneal Pharmaceuticals, reported transactions involving Class A Common Stock.
- Boyer acquired 31,371 shares of Class A Common Stock through the vesting of restricted stock units.
- Simultaneously, 11,737 shares were withheld to satisfy tax obligations at a price of $8.67 per share.
- Following these transactions, Boyer directly owns 276,304 shares of Class A Common Stock.
- The restricted stock units were granted on March 1, 2021, and vest in four equal annual installments.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their trading activities. This filing indicates routine vesting of previously granted equity compensation.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares.
- The withholding of shares for taxes reduces the number of shares entering the market.
Key Dates
| Date | Description |
|---|---|
| 03/01/2021 | Reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/01/2025 | Date of transaction: vesting of restricted stock units and withholding of shares for tax obligations. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.